262 related articles for article (PubMed ID: 20570206)
1. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Lieu CA; Kunselman AR; Manyam BV; Venkiteswaran K; Subramanian T
Parkinsonism Relat Disord; 2010 Aug; 16(7):458-65. PubMed ID: 20570206
[TBL] [Abstract][Full Text] [Related]
2.
Cilia R; Laguna J; Cassani E; Cereda E; Pozzi NG; Isaias IU; Contin M; Barichella M; Pezzoli G
Neurology; 2017 Aug; 89(5):432-438. PubMed ID: 28679598
[TBL] [Abstract][Full Text] [Related]
3. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
[TBL] [Abstract][Full Text] [Related]
4. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-Reduced
Johnson SL; Park HY; DaSilva NA; Vattem DA; Ma H; Seeram NP
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30131460
[No Abstract] [Full Text] [Related]
6. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
[TBL] [Abstract][Full Text] [Related]
7. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of extract of Bacopa monnieri and Mucuna pruriens as neuroprotectant in MPTP model of Parkinson’s disease.
Singh B; Pandey S; Verma R; Ansari JA; Mahdi AA
Indian J Exp Biol; 2016 Nov; 54(11):758-66. PubMed ID: 30179419
[TBL] [Abstract][Full Text] [Related]
9. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
10. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
[TBL] [Abstract][Full Text] [Related]
11. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Feb; 18(2):97-101. PubMed ID: 15022157
[TBL] [Abstract][Full Text] [Related]
12. The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate.
Lieu CA; Venkiteswaran K; Gilmour TP; Rao AN; Petticoffer AC; Gilbert EV; Deogaonkar M; Manyam BV; Subramanian T
Evid Based Complement Alternat Med; 2012; 2012():840247. PubMed ID: 22997535
[TBL] [Abstract][Full Text] [Related]
13. Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson's disease.
Poddighe S; De Rose F; Marotta R; Ruffilli R; Fanti M; Secci PP; Mostallino MC; Setzu MD; Zuncheddu MA; Collu I; Solla P; Marrosu F; Kasture S; Acquas E; Liscia A
PLoS One; 2014; 9(10):e110802. PubMed ID: 25340511
[TBL] [Abstract][Full Text] [Related]
14. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G
Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722
[TBL] [Abstract][Full Text] [Related]
15.
Kamkaen N; Chittasupho C; Vorarat S; Tadtong S; Phrompittayarat W; Okonogi S; Kwankhao P
Molecules; 2022 May; 27(10):. PubMed ID: 35630617
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the anti-diabetic properties of Mucuna pruriens seed extract.
Majekodunmi SO; Oyagbemi AA; Umukoro S; Odeku OA
Asian Pac J Trop Med; 2011 Aug; 4(8):632-6. PubMed ID: 21914541
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Ndlovu BC; Daniels WM; Mabandla MV
Neurotox Res; 2016 Jan; 29(1):126-34. PubMed ID: 26459303
[TBL] [Abstract][Full Text] [Related]
19. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
20. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model.
Yadav SK; Prakash J; Chouhan S; Singh SP
Neurochem Int; 2013 Jun; 62(8):1039-47. PubMed ID: 23562769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]